XML 45 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
SEGMENT REPORTING
 9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
SEGMENT REPORTING

NOTE 10 – SEGMENT REPORTING

 

Operating segments are defined as the components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision makers in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision makers direct the allocation of resources to operating segments based on the profitability, cash flows, and growth opportunities of each respective segment.

 

The Company classifies its business interests into reportable segments which are:

 

●Trxade, Inc. - Web based pharmaceutical marketplace platform – B2B sales
●CSP - Community Specialty Pharmacy, LLC – Licensed retail pharmacy – B2C sales
●Integra - Integra Pharma, LLC - Licensed wholesaler of brand, generic and non-drug products – B2B sales
●Unallocated - Other – corporate overhead expense, Alliance Pharma Solutions, LLC and Bonum Health, LLC

 

Nine Months Ended September 30, 2022  Trxade, Inc.   CSP   Integra   Unallocated   Total 
Revenue  $4,001,670   $905,083   $3,949,772   $62,787   $8,919,312 
Gross Profit   4,001,670    (114,387)   (41,462)   62,787    3,908,608 
Segment Assets   1,853,474    236,827    454,783    2,111,177    4,689,261 
Segment Profit (Loss )   1,320,138    (363,212)   (493,203)   (3,070,562)   (2,606,839)
Cost of Sales  $-   $1,019,470  $3,991,234  $-   $5,010,704

 

Nine Months Ended September 30, 2021  Trxade, Inc.   CSP   Integra   Unallocated   Total 
Revenue  $3,653,269   $1,287,296   $2,511,270   $49,700   $7,501,535 
Gross Profit   3,652,015    123,470    (319,104)   49,362    3,505,743 
Segment Assets   1,487,657    (404,174)   563,396    3,867,221    5,514,101 
Segment Profit (Loss)   1,511,809    (89,025)   (2,500,032)   (3,454,295)   (4,531,543)
Cost of Sales  $1,254   $1,163,826   $2,830,374   $338   $3,995,792